Protalix BioTherapeutics, Inc. company info

CIK 1006281
IRS Number 650643773
State of incorporation DE
Business address 2 SNUNIT ST
SCIENCE PARK, POB 455
CARMIEL
L3
20100
Mail address 2 SNUNIT ST
SCIENCE PARK, POB 455
CARMIEL
L3
20100

Short summary

Protalix BioTherapeutics, Inc. is a Israel company, with head office located at 2 Snunit St Carmiel, Israel 20100. In 2018 the company owned a total of 55.24 million USD worth of assets, including 41.60 million USD worth of current assets. 2013 was the year when the company amassed the most assets.

Protalix BioTherapeutics, Inc. Income Statement

Name [in Millions USD]20082009201020112012201320142015201620172018Trends
Gross Profit -3.196.861.4426.286.092.893.630.804.01
Selling, General and Administrative Expense 9.768.399.237.289.3611.5310.92
Research and development 27.3937.6937.8236.6733.3127.3524.8930.4132.1735.53
Operating Income (Loss) -31.97-29.97-36.53-12.17-27.12-28.56-23.67-33.16-36.35-19.31
Interest expense 1.023.553.55
Net income -31.44-29.00-36.53-11.62-27.79-29.9458.04-29.37-83.44-26.46

Protalix BioTherapeutics, Inc. Balance Sheet

Name [in Millions USD]20082009201020112012201320142015201620172018Trends
Cash and cash equivalents 42.6054.9644.0559.2833.1371.1443.2454.6334.5328.3325.10
Accounts Receivable, Net, Current 1.721.542.032.101.941.493.015.257.26
Inventories 0.541.037.197.146.376.077.066.987.00
Property, Plant and Equipment, Gross 29.4231.1032.0332.7433.5534.3035.1435.51
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment 11.1514.7918.3221.4523.8025.6027.4729.12
Other Assets, Noncurrent 1.752.04
Total assets 71.8984.3062.3196.6565.9578.865951.7255.24
Current assets 51.2065.8945.9382.3653.8767.6548.8943.0541.60
Accounts payable 6.805.537.509.3110.27
Total current liabilities 20.2821.3326.6327.1825.5211.4619.1218.4925.99
Long-term Debt, Excluding Current Maturities 4.454.680.380.91
Deferred Revenue, Noncurrent 54.0548.6445.1239.5135.610.6231.8961.78
Total liabilities 80.5976.4474.29136.44131.0986.8479.6794.46122.73
Common Stock, Value, Issued 0.080.090.090.090.090.100.120.140.15
Retained Earnings (Accumulated Deficit) -135.45-171.98-183.60-211.39-241.33-183.29-212.66-296.10337.60

Protalix BioTherapeutics, Inc. Cash Flow

Name [in Millions USD]20082009201020112012201320142015201620172018Trends
Net income -31.44-29.00-36.53-11.62-27.79-29.9458.04-29.37-83.44-26.46
Depreciation 3.693.543.142.371.981.921.67
Accounts receivable 1.226.86-3.89-0.24-1.901.01-0.521.13-0.033.10
Inventories 1.19-0.913.763.923.452.32-0.522.590.74
Deferred revenue 64.61-4.56-3.011.28-7.160.890.36-0.4126.01
Net Cash Provided by (Used in) Operating Activities 44.45-38.46-23.570.64-30.65-29.28-24.28-32.10-9.99-7.74
Payments to Acquire Property, Plant, and Equipment 6.207.865.712.071.890.790.460.850.970.69
Net Cash Provided by (Used in) Investing Activities -6.17-7.99-5.87-2.29-2.10-1.0039.39-0.97-1.12-0.59
Net Cash Provided by (Used in) Investing Activities, Continuing Operations -5.87-2.29-2.10-1.00-0.51-0.97-1.12
Net Cash Provided by (Used in) Financing Activities 0.290.5020.9326.566.6419.70-1.42-4.75
Cash and Cash Equivalents, Period Increase (Decrease) 38.67-45.37-8.9025.0334.36-31.6321.61-13.09-12.12-13.36